This trial investigated long-term (56-week treatment/24-week follow-up) use of subcutaneous tanezumab (5 or 10 mg every 8 weeks) or oral celecoxib (200 mg/day) in Japanese patients with chronic low back pain. Tanezumab safety was consistent with previous studies, except overall adverse events (tanezumab 5 mg = 63.0%, tanezumab 10 mg = 54.8%, celecoxib = 67.4%) and events of abnormal peripheral sensation (tanezumab 5 mg = 9.8%, tanezumab 10 mg = 4.3%, celecoxib = 4.3%) were more frequent with 5 mg than 10 mg tanezumab. Joint safety event rates were 1.1% for tanezumab 5 mg, 2.2% for tanezumab 10 mg and 0% for celecoxib. All treatments improved pain and function throughout the treatment period. NCT02725411.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2217/pmt-2021-0040 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Metabolic syndrome, radiographic osteoarthritis progression and chronic pain of the knee among men and women from the general population: The Rotterdam study.
Semin Arthritis Rheum
December 2024
Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, the Netherlands; Department of Epidemiology, Erasmus MC, University Medical Center Rotterdam, the Netherlands; Department of Orthopedics & Sports Medicine, Erasmus MC, University Medical Center Rotterdam, the Netherlands. Electronic address:
Objective: Although a relationship between osteoarthritis and components of metabolic syndrome (MetS) has been suggested, most of the results have been cross-sectional. We, therefore, aimed to investigate the sex-specific longitudinal association of (components of) MetS with progression of radiographic osteoarthritis and chronic pain in the knee joints in a large prospective cohort.
Method: In the large population-based Rotterdam study of up to 6,138 individuals, median follow-up time 5.
Re: Re: Laboratory safety evaluation of bedinvetmab, a canine anti-nerve growth factor monoclonal antibody, in dogs.
Vet J
August 2024
Zoetis Veterinary Medical Research and Development; Global Pharmacokinetics, Dynamics, Metabolism and Safety, 333 Portage St, Kalamazoo, MI 49007, United States.
In their letter to the editor, Farrell et al., (2024) presented questions related to canine joint health after treatment with the anti-Nerve Growth Factor (NGF) monoclonal antibody (mAb) bedinvetmab, which was presented as a component of a non-clinical laboratory safety assessment published in Krautmann et al., (2021).
View Article and Find Full Text PDFThe Polyanalgesic Consensus Conference (PACC)®: Intrathecal Drug Delivery Guidance on Safety and Therapy Optimization When Treating Chronic Noncancer Pain.
Neuromodulation
October 2024
Neurosurgical Services, Anesthesia Pain Care Consultants, Tamarac, FL, USA.
Article Synopsis
- The International Neuromodulation Society organized a diverse group of experts to create guidelines for using intrathecal drug delivery in chronic pain management based on two decades of research.
- Authors were selected for their expertise and conducted thorough literature reviews to ensure the recommendations were evidence-based.
- The resulting guidelines aim to improve the safety and effectiveness of intrathecal drug delivery, with plans for future updates as new research becomes available.
Effect size varies based on calculation method and may affect interpretation of treatment effect: an illustration using randomised clinical trials in osteoarthritis.
Adv Rheumatol
April 2024
Pfizer Inc, Groton, CT, USA.
Article Synopsis
- The study investigates how different methods for calculating effect sizes (ES) can influence results, using data from three trials of tanezumab for osteoarthritis pain.
- Three approaches for computing pooled standard deviation (SD) — Baseline, Endpoint, and Median — were compared, revealing significant differences in ES across these methods.
- The researchers emphasize the need for transparency in reporting ES calculations, as these differences can impact treatment effect interpretations and sample size determinations for clinical trials.
Various Doses of Tanezumab in the Management of Chronic Low Back Pain (CLBP): A Pooled Analysis of 4,514 Patients.
Cureus
October 2023
General Medicine, Gandhi Medical College, Hyderabad, IND.
Chronic low back pain (CLBP) is a persistent and debilitating condition characterized by pain and discomfort in the lower back region that lasts more than 12 weeks. This review aims to determine the efficacy and safety of various doses of tanezumab for managing CLBP. The present meta-analysis was reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines and the Cochrane Handbook for Systematic Reviews of Intervention standards.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!